Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lanraplenib succinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib succinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 598 | 5日内发货 | ||
5 mg | ¥ 987 | 5日内发货 | ||
10 mg | ¥ 1,730 | 5日内发货 | ||
100 mg | ¥ 7,890 | 6-8周 |
Lanraplenib succinate 的其他形式现货产品:
产品描述 | Lanraplenib succinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib succinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. |
靶点活性 | Syk:9.5 nM |
体外活性 | In human macrophages, Lanraplenib succinate inhibits IC-stimulated TNFα and IL-1β release (EC50=121±77 nM and 9±17 nM, respectively). Lanraplenib succinate ?inhibits glycoprotein VI (GPVI)-induced phosphorylation of linker for activation of T cells and phospholipase Cγ2, platelet activation and aggregation in human whole blood, and platelet binding to collagen under arterial flow.Lanraplenib succinate ?inhibits anti-IgM stimulated phosphorylation of AKT, BLNK, BTK, ERK, MEK, and PKCδ in human B cells with EC50 values of 24-51 nM.?Lanraplenib monosuccinate inhibits anti-IgM mediated CD69 and CD86 expression on B-cells (EC50=112±10 nM and 164±15 nM, respectively) and anti-IgM /anti-CD40 co-stimulated B cell proliferation (EC50=108±55 nM). |
别名 | GS-9876 succinate |
分子量 | 1241.294 |
分子式 | C58H68N18O14 |
CAS No. | 1800047-00-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (134.26 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 0.8056 mL | 4.0281 mL | 8.0561 mL | 20.1403 mL |
5 mM | 0.1611 mL | 0.8056 mL | 1.6112 mL | 4.0281 mL | |
10 mM | 0.0806 mL | 0.4028 mL | 0.8056 mL | 2.014 mL | |
20 mM | 0.0403 mL | 0.2014 mL | 0.4028 mL | 1.007 mL | |
50 mM | 0.0161 mL | 0.0806 mL | 0.1611 mL | 0.4028 mL | |
100 mM | 0.0081 mL | 0.0403 mL | 0.0806 mL | 0.2014 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lanraplenib succinate 1800047-00-0 Angiogenesis Tyrosine Kinase/Adaptors Syk GS-9876 Succinate GS-9876 succinate Lanraplenib Succinate GS 9876 Succinate GS9876 Succinate Inhibitor inhibitor inhibit